The relationship between body mass index and survival in patients with renal cell carcinoma treated with nivolumab.

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2025-02-23 DOI:10.1080/1120009X.2025.2469371

Rumeysa Çolak, İlkay Gültürk, Gülhan Dinç, Goncagül Akdağ, Sedat Yıldırım, Mesut Yılmaz, Deniz Tural

{"title":"The relationship between body mass index and survival in patients with renal cell carcinoma treated with nivolumab.","authors":"Rumeysa Çolak, İlkay Gültürk, Gülhan Dinç, Goncagül Akdağ, Sedat Yıldırım, Mesut Yılmaz, Deniz Tural","doi":"10.1080/1120009X.2025.2469371","DOIUrl":null,"url":null,"abstract":"Introduction: Immunotherapies have increased the therapeutic options for patients with metastatic renal cell carcinoma (mRCC), but the absence of prognostic indicators remains unresolved. We assessed the potential association of BMI with the overall survival (OS) of patients treated with nivolumab.Methods: We performed a retrospective study of 126 patients with histologically confirmed mRCC who began systemic ICI therapy between January 2016 and April 2022 were included. BMI at the time of treatment start was calculated. Then patients were divided into two groups: high BMI (≥25) and low BMI (<25). Therapeutic responses were determined according to RECIST v1.1. OS was defined as the time from starting ICI treatment until death or last follow-up at the data cutoff.Results: The cohort was male 74.6%, with a median age of 62. The median follow-up time was 18.6 months. The patients were classified as low BMI (<25) and high BMI (≥25). The OS was 40.6 months (95% CI: 34.2-47.0) for patients with high BMI vs. 9.4 months (95% CI: 7.0-11.7) for patients with low BMI, and a significant association was found between BMI and OS (p < 0.001).Conclusions: BMI was an independent prognostic factor in the patients with mRCC treated with nivolumab. Prospective and multicenter research is needed to confirm our findings.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2469371","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immunotherapies have increased the therapeutic options for patients with metastatic renal cell carcinoma (mRCC), but the absence of prognostic indicators remains unresolved. We assessed the potential association of BMI with the overall survival (OS) of patients treated with nivolumab.

Methods: We performed a retrospective study of 126 patients with histologically confirmed mRCC who began systemic ICI therapy between January 2016 and April 2022 were included. BMI at the time of treatment start was calculated. Then patients were divided into two groups: high BMI (≥25) and low BMI (<25). Therapeutic responses were determined according to RECIST v1.1. OS was defined as the time from starting ICI treatment until death or last follow-up at the data cutoff.

Results: The cohort was male 74.6%, with a median age of 62. The median follow-up time was 18.6 months. The patients were classified as low BMI (<25) and high BMI (≥25). The OS was 40.6 months (95% CI: 34.2-47.0) for patients with high BMI vs. 9.4 months (95% CI: 7.0-11.7) for patients with low BMI, and a significant association was found between BMI and OS (p < 0.001).

Conclusions: BMI was an independent prognostic factor in the patients with mRCC treated with nivolumab. Prospective and multicenter research is needed to confirm our findings.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.